PKO Investment Management Joint Stock Co Invests $905,000 in Bristol-Myers Squibb (NYSE:BMY)

PKO Investment Management Joint Stock Co purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 16,000 shares of the biopharmaceutical company's stock, valued at approximately $905,000.

Other institutional investors also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $25,000. Park Square Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $26,000. Fairway Wealth LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $28,000. Transce3nd LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $28,000. Finally, Comprehensive Financial Planning Inc. PA acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $34,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Up 0.9%

NYSE:BMY traded up $0.41 during trading hours on Friday, hitting $48.26. 20,756,575 shares of the company's stock traded hands, compared to its average volume of 13,134,972. The firm has a market cap of $98.21 billion, a P/E ratio of -10.92, a P/E/G ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock's fifty day moving average price is $50.49 and its two-hundred day moving average price is $55.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same period in the previous year, the firm earned ($4.40) earnings per share. Bristol-Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. On average, research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.14%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's payout ratio is currently 92.88%.

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 4,250 shares of the company's stock in a transaction on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.09% of the company's stock.

Analysts Set New Price Targets

BMY has been the subject of several research analyst reports. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Piper Sandler initiated coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Finally, Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.